Expression Profiling of microRNA Following Administration of Dexmedetomidine

Coronary Disease Clinical Trial

Official title:

Expression Profiling of microRNA Following Administration of Dexmedetomidine in Patients Undergoing Procedures

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03213743
• Other study ID #: 1stKunmingMCQJQ
• Status: Completed
• Phase: N/A
• First received: July 7, 2017
• Last updated: July 10, 2017
• Start date: June 19, 2017
• Est. completion date: June 21, 2017

Study information

• Verified date: July 2017
• Source: The First Affiliated Hospital of Kunming Medical College
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to find out the differential expression profiling of microRNA before and after adiministration of dexmedetomidine in patients undergoing procedures, and then investigators will do some in vitro studies to validate the functions of the microRNA.

Description:

Background and objective: The use of dexmedetomidine may have benefits on the clinical outcomes of cardiac surgery. MicroRNAs are non-coding RNA sequences that act as regulators of gene expression. Investigators conduct a study to determine the role of microRNAs in cardioprotection mediated by dexmedetomidine.

Methods: In this study 3 patients were selected. The blood sample were taken before administration of dexmedetomidine.Investigators infused loading dose of dexmedetomidine for 10 minutes and maintaining dese of dexmedetomidine for 20 minutes.Thirty minutes after the administration, another blood samples were taken and stored in the liquid nitrogen and both the samples were marked. Those sample were analyzed for differentially expressed microRNA with Exiqon miRNA Array.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3
• Est. completion date: June 21, 2017
• Est. primary completion date: June 21, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

• The patients without arrithmia will undergo procedure.

Exclusion Criteria:

• The patients have bradycardia (hear rate is less than 60 beats per minute) or conduction block.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease

Intervention

Drug:
• Dexmedetomidine Injection
Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.

Locations

Country	Name	City	State
China	Jinqiao Qian	Kunming	Yunnan

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Kunming Medical College

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	microRNA differential expression	microRNA differential expression exerts cardioprotection effect on patients undergoing procedures.	30 minutes